Navigation Links
Data Analyses Outline Efficacy and Safety of Mircera for the,Treatment of Renal Anemia Associated With Chronic Kidney Disease

ORLANDO, Fla. and NUTLEY, N.J., April 12, 2007 /PRNewswire-FirstCall/ -- Data analyses from the largest initial registration clinical trial program ever undertaken in the renal anemia arena provide efficacy and safety information on the investigational anemia therapy MIRCERA(TM) for the treatment of renal anemia associated with chronic kidney disease (CKD) in patients on dialysis and not on dialysis. Three data analyses were presented at the National Kidney Foundation 2007 Spring Clinical Meetings in Orlando, Florida.

According to these analyses, MIRCERA with extended dosing up to once every four weeks: (1) corrected and maintained hemoglobin (Hb) levels in patients with CKD, on dialysis and not on dialysis; (2) maintained Hb levels in dialysis patients, regardless of congestive heart failure (CHF) status as shown in a post-hoc analysis; and (3) exhibited a safety profile that is consistent with that of commercially available erythropoiesis stimulating agents (ESAs) and typical of those associated with this patient population.

"The goal in treating renal anemia is to safely maintain target hemoglobin levels," said Steven Fishbane, MD, Associate Director of Nephrology, Associate Chairman of the Department of Medicine, and Director of End-Stage Renal Disease research at Winthrop University Hospital. "These data analyses clearly demonstrate that MIRCERA corrected low hemoglobin levels, and maintained target hemoglobin levels with the added convenience of up to once- monthly dosing."

About the Studies

Safety and Tolerability of C.E.R.A. In Patients With Chronic Kidney Disease: Pooled Data From Ten Phase II-III Trials

Pooled data from four Phase II and six Phase III studies evaluated the safety and tolerability of MIRCERA (intravenous (IV) and subcutaneous (SC)) in patients not previously treated with commercially available ESAs and those previously treated with commercially availa
'"/>




Page: 1 2 3 4

Related medicine technology :

1. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
2. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Safety Analyses of Clinical Data for Bifeprunox in Patients with Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar to Placebo
5. Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show
6. Prospective Model Outlined Potential Time and Cost Savings of Once-Monthly Anemia Treatment
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
10. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
11. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
Post Your Comments:
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets  has ... Pipeline Insight 2014" report to their offering. ... is one of the largest segments of pharmaceuticals industry. The ... while the available therapies were unable to meet the market ... market for CNS disorder, especially over the past two decades. ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Research and Development Trend Forecast of Pharmaceutical Equipment ... Research and Development Trend Forecast of ... 2014-2018 mainly analyzes China,s pharmaceutical ... supply & demand, competition landscape, and business performance of ...
(Date:8/29/2014)... , August 29, 2014 ... Market by Product & Services (Equipment, Reagent, Primer, ... Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, ... MarketsandMarkets, the global Oligonucleotide Synthesis Market is expected ... Million in 2014, growing at a CAGR of ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4
... Compare Genous vs. Drug-Eluting and Bare ... ... in the,randomized TRIAS (TRI-stent Adjudication Study) trial of OrbusNeich,s,Genous Bio-engineered R ... April, according to Robbert de Winter, M.D., Ph.D.,principal investigator and director ...
... 16 Protocol Driven Healthcare,Inc. (PDHI) today ... Hallmark Insights to provide fully integrated incentive ... ConXus health improvement platform. ConXus Rewards ... points earned by participants completing activities within ...
Cached Medicine Technology:Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) 2PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs 2
(Date:8/31/2014)... August 31, 2014 Healthy Grid ... cavities. Loloz lollipops will use herbs to fight ... hard candies will also fight bacteria while stimulating saliva production. ... together,” said Andrew Clapp of Healthy Grid. “Even though personal ... can always use a little more prevention. Cavities are painful ...
(Date:8/31/2014)... CO (PRWEB) August 31, 2014 ... released award winning, “Simplicity & Sophistication: Short Stories ... written and narrated by Dr. James W. Jackson author, ... Sophistication,” Dr. Jackson compresses his vast volume ... four decades into over 150 countries on behalf of ...
(Date:8/31/2014)... 2014: Renal denervation seems to be more successful at ... it includes accessory renal arteries, according to research presented ... Germany. , Dr Schmiedel said: "More than one billion ... as blood pressure (BP) greater than 140/90 mmHg. Up ... and are unable to reduce BP below 140/90 mmHg ...
(Date:8/30/2014)... Sunday 31 August 2014: Local anaesthetic is as safe ... general anaesthetic, according to results of the FRANCE 2 ... Chopard from France. , Dr Chopard said: "Numerous studies ... for patients with severe symptomatic aortic stenosis who are ... aortic valve replacement. The number of TAVI procedures in ...
(Date:8/30/2014)... Not only is USHEALTH Advisors now on pace ... its highest level of late-summer sales, including a new company ... to set a new record in 2014,” stated USHEALTH Advisors ... in both weekly annualized volume and the amount of writing ... August, we saw even more of our agents enjoying tremendous ...
Breaking Medicine News(10 mins):Health News:Healthy Grid: Fight Cavities With Sweet Treats 2Health News:Healthy Grid: Fight Cavities With Sweet Treats 3Health News:Brook Forest Voices Announces End of Summer Release! Dr. James Jackson’s, “Simplicity & Sophistication” Audiobook 2Health News:Renal denervation more successful when it includes accessory arteries 2Health News:Local anesthetic for TAVI as safe and effective as general anesthetic 2Health News:USHEALTH Advisors, LLC Continues Its Record-Setting Sales Pace 2
... For his dedication to advancing the diversity of doctoral-level ... the American Association for the Advancement of Science (AAAS) ... DeSimonewho serves as both the Chancellor,s Eminent Professor of ... Hill (UNC), and as the William R. Kenan, Jr. ...
... (BWH) was selected by the Centers for Medicare & ... a demonstration project that promotes appropriate utilization of advanced ... was selected as a convener under the Medical Imaging ... Medical Center-Physician Hospital Organization; University of Wisconsin Hospital Foundation, ...
... Amanda Gardner HealthDay Reporter , WEDNESDAY, Feb. 16 ... state-of-the-nation,s health report and the news is mixed, with life ... On the positive side, life expectancy was up slightly ... beginning of the decade. And while women are still ...
... the unpredictable economy, nearly three-quarters (73%) of New Jersey ... globally is important to jobs and incomes in the ... Research!America. The poll data will be released today at ... research and development (R&D) experts and New Jersey business, ...
... (HealthDay News) -- Americans living in parts of Appalachia ... active in their free time, according to federal government ... least likely to be physically active during leisure time ... inactivity rates are 29.2 percent or greater for more ...
... , WEDNESDAY, Feb. 16 (HealthDay News) -- Many American parents ... and cold medicines to their kids despite U.S. Food and ... In response to research linking over-the-counter (or OTC) cough and ... ages 2 years and younger, the FDA said in 2008 ...
Cached Medicine News:Health News:2010 AAAS Mentor Award goes to Dr. Joseph M. DeSimone of the University of North Carolina at Chapel Hill, and North Carolina State University 2Health News:2010 AAAS Mentor Award goes to Dr. Joseph M. DeSimone of the University of North Carolina at Chapel Hill, and North Carolina State University 3Health News:2010 AAAS Mentor Award goes to Dr. Joseph M. DeSimone of the University of North Carolina at Chapel Hill, and North Carolina State University 4Health News:Brigham and Women's Hospital selected to participate in Medicare imaging demonstration project 2Health News:Brigham and Women's Hospital selected to participate in Medicare imaging demonstration project 3Health News:America's Health a Mixed Bag: Report 2Health News:America's Health a Mixed Bag: Report 3Health News:Most New Jersey residents see global health as critical to state's economy 2Health News:Most New Jersey residents see global health as critical to state's economy 3Health News:Appalachia, the South Home to Least-Active Americans: CDC 2Health News:Parents Still Giving Cough, Cold Meds to Kids Under 2: Poll 2
... A product you can trust its ... perform retinal, cataract, and glaucoma therapy ... III Combi is the optimal system ... and combined iridotomy. The push of ...
... YAG III is the new disruption ... in particular for applications in posterior ... the YAG laser is also used ... IOL polishing. It's another milestone in ...
... is a top quality Carl Zeiss Meditec ... vision defects even safer, more patient-friendly and ... work platform are oriented towards increasing efficiency, ... recovery of vision. Key factors here are ...
An aid for advancing a pacemaker lead through the subcutaneous tissue of the chest wall to the pacemaker pocket....
Medicine Products: